Galectin Therapeutics (GALT) Competitors

Upstream Bio (NASDAQ:UPB) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings.

Which has better earnings and valuation, UPB or GALT?

Upstream Bio has higher revenue and earnings than Galectin Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.37M	135.89	N/A	N/A	N/A
Galectin Therapeutics	N/A	N/A	-$41.07M	-$0.73	-1.70

Does the media prefer UPB or GALT?

In the previous week, Galectin Therapeutics had 5 more articles in the media than Upstream Bio. MarketBeat recorded 8 mentions for Galectin Therapeutics and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.77 beat Galectin Therapeutics' score of -0.19 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in UPB or GALT?

Galectin Therapeutics received 343 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 100.00% of users gave Upstream Bio an outperform vote while only 59.01% of users gave Galectin Therapeutics an outperform vote.

Company	Underperform	Outperform
Upstream Bio	Outperform Votes 4 100.00%	Underperform Votes No Votes
Galectin Therapeutics	Outperform Votes 347 59.01%	Underperform Votes 241 40.99%

Is UPB or GALT more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	N/A	N/A	N/A
Galectin Therapeutics	N/A	N/A	-163.15%

Do institutionals & insiders believe in UPB or GALT?

11.7% of Galectin Therapeutics shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Do analysts rate UPB or GALT?

Upstream Bio currently has a consensus price target of $56.50, suggesting a potential upside of 841.04%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 784.24%. Given Upstream Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Upstream Bio is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Galectin Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Upstream Bio beats Galectin Therapeutics on 7 of the 11 factors compared between the two stocks.